REUTERS
January 26, 2021 at 18:20 JST
A vaccine candidate developed by Shionogi & Co., together with the National Institute of Infectious Diseases and other entities (Provided by Shionogi & Co.)
Japanese drugmaker Shionogi & Co. said on Tuesday it has sold the development and marketing rights for a COVID-19 treatment to California-based biotech BioAge Labs Inc.
The Japanese drugmaker said in a statement that it had discovered the drug, known as BGE-175, which was under development to treat allergic rhinitis.
BioAge will have exclusive rights to BGE-175 for the treatment of COVID-19 in the United States and Europe in exchange for an upfront payment as well as milestones and royalties.
The U.S. biotech plans to start a Phase II trial of the drug for COVID-19 in the first half of 2021.
Shionogi is also developing a recombinant protein vaccine for COVID-19 that is now in combined Phase I and II trials in Japan.
The company is betting on a proven platform to help it become Japan’s biggest home-grown COVID-19 vaccine producer
1st case in Japan of Kawasaki disease in child with COVID-19
September 12, 2020Fujifilm to start U.S. clinical trial of Avigan for COVID-19
April 9, 2020Asahi, World Economic Forum to host COVID-19 discussion on Sept. 21
September 19, 2020
Tokyo’s strained medical system now at highest alert level
December 17, 2020WHO moves to update COVID-19 guidance after ‘great news’ in drug study
June 17, 2020
Stories about memories of cherry blossoms solicited from readers
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
A series on the death of a Japanese woman that sparked a debate about criminal justice policy in the United States
A series about Japanese-Americans and their memories of World War II
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.
